CRDF
CRDF
NASDAQ · Biotechnology

Cardiff Oncology Inc

$1.20
-0.04 (-3.23%)
As of Sep 28, 10:22 PM ET ·
Financial Highlights (FY 2026)
Revenue
692.4K
Net Income
-53,367,541
Gross Margin
100.0%
Profit Margin
-7,732.0%
Rev Growth
+15.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 100.0% 100.0% 56.1% 56.1%
Operating Margin -8,256.3% -7,430.7% -18.4% -15.5%
Profit Margin -7,732.0% -7,345.4% -21.6% -17.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 692.4K 602.1K 16.05M 19.98M
Gross Profit 692.4K 602.1K 9.01M 11.22M
Operating Income -57,164,860 -44,741,607 -2,950,777 -3,087,601
Net Income -53,367,541 -41,769,533 -3,462,613 -3,502,482
Gross Margin 100.0% 100.0% 56.1% 56.1%
Operating Margin -8,256.3% -7,430.7% -18.4% -15.5%
Profit Margin -7,732.0% -7,345.4% -21.6% -17.5%
Rev Growth +15.0% +15.0% +0.8% +4.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 38.47M 47.77M
Total Equity — — 57.67M 59.42M
D/E Ratio — — 0.67 0.80
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -56,557,146 -46,725,183 -3,307,317 -3,822,507
Free Cash Flow — — -2,137,974 -3,204,130